Atea Pharmaceuticals, Inc.
AVIR
$4.49
$0.143.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 159.32M | 146.53M | 120.09M | 102.15M | 93.00M |
| Gross Profit | -159.32M | -146.53M | -120.09M | -102.15M | -93.00M |
| SG&A Expenses | 30.28M | 32.86M | 39.10M | 42.93M | 46.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 189.60M | 179.40M | 159.19M | 145.07M | 139.08M |
| Operating Income | -189.60M | -179.40M | -159.19M | -145.07M | -139.08M |
| Income Before Tax | -175.83M | -164.51M | -146.19M | -135.27M | -138.59M |
| Income Tax Expenses | -6.32M | -6.16M | 831.00K | 861.00K | 897.00K |
| Earnings from Continuing Operations | -169.52 | -158.35 | -147.03 | -136.13 | -139.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -169.52M | -158.35M | -147.03M | -136.13M | -139.49M |
| EBIT | -189.60M | -179.40M | -159.19M | -145.07M | -139.08M |
| EBITDA | -189.18M | -178.98M | -158.77M | -144.66M | -138.66M |
| EPS Basic | -2.12 | -1.95 | -1.78 | -1.61 | -1.65 |
| Normalized Basic EPS | -1.38 | -1.26 | -1.06 | -0.92 | -0.85 |
| EPS Diluted | -2.12 | -1.95 | -1.78 | -1.61 | -1.65 |
| Normalized Diluted EPS | -1.38 | -1.26 | -1.06 | -0.92 | -0.85 |
| Average Basic Shares Outstanding | 320.12M | 326.09M | 332.42M | 337.79M | 338.30M |
| Average Diluted Shares Outstanding | 320.12M | 326.09M | 332.42M | 337.79M | 338.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |